Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 8OTHER 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Radiotherapy 214Cisplatin 180Cyclophosphamide 169Doxorubicin 138Vincristine 127Paclitaxel 125Filgrastim 121Etoposide 104Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NETWORK × prexasertib × Clear all
NCT02808650 2023-12-20

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
30 enrolled 16 charts
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡